Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q1 FY2019 Earnings Presentation
18 slides from Dr. Lal Pathlabs's earnings presentation, Aug 10, 2018
Slide 1: Dr. Lal PathLabs Limited Q1 FY19 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q1 FY19 Results Presentation August 10, 2018
Slide 2: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 3: Q1 FY19 Snapshot
Q1 FY19 Snapshot 17.3% Revenues INR 2,923 mn Samples Processed ~9.90 mn 16.7% EBITDA INR 793 mn Patients Tested ~4.23 mn 11.7% PAT INR 497 mn Total Employees* ~4,316 *As on March 31, 2018, 3
Slide 4: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Performance Highlights 3 Financial Table 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Shareholding 10 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at
Slide 5: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs 193 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi and Regional Ref lab at diagnostic services Kolkata), 2,153 Patient Service Centers (PSCs) and 5,624 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1110 t
Slide 6: Key Performance Highlights
Key Performance Highlights Trend of volume improvement continues in Q1. Patient volumes and tests per patients show healthy increase. During Q1 FY19: • Revenues increased to Rs. 2,923 million in Q1 FY19, up 17.3% driven by 18.1% volume improvement • Number of patients tested stood at 4.23 million in
Slide 7: Financial Table
Financial Table Particulars (Rs. mn) Q1 FY19 Q1 FY18 Growth % FY2018 Total Revenue 2,922.8 2,492.6 17.3% 10,569.2 Total Expenditure 2,172.5 1,837.5 7,929.2 EBITDA 750.3 655.1 14.5% 2,640.0 Adj for RSU, and stock based comp. & CSR Cost 43.0 24.8 142.7 Normalised operating EBITDA 793.3 679.9 16.7% 2,7
Slide 8: Financial Highlights
Financial Highlights Revenues All figures in Rs. mn 2,923 Q1 reported continued 2,493 improvement in revenues at Realisation per patient largely 17.3% to Rs. 2,923 million. Key flat at Rs. 691 vs Rs. 694 in JQ aspects of performance were: last year mainly due to price rationalisation in select m
Slide 9: Financial Highlights
Financial Highlights PBT All figures in Rs. mn 754 660 Q1 PBT stood at Rs. 753.5 million PBT margin at 25.8% during vs. Rs. 660.3 million in same the quarter was marginally quarter last year lower than previous year at 26.5% Q1 FY18 Q1 FY19 PAT 497 444 Q1 PAT at Rs. 496.5 million as Q1 PAT m
Slide 10: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs 2153 No. of PUPs 1,759 189 193 1,559 164 172 1,340 5,668 5624 4,967 5,021 FY15 FY16 FY17 FY18 FY15 FY16 FY17 FY18 FY15 FY16 FY17 FY18 No. of patients (mn) No. of samples (mn) 15.2 13.3 34.7 12.0 29.3 9.9 26.3 21.7 4.2 9.9 FY15 FY16 FY17 F
Slide 11: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “We have started the year on a strong note with healthy topline growth of 17% during the quarter led by our disciplined approach of driving patient volumes through focus on quality, ac
Slide 12: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services Initiatives to improve brand con
Slide 13: Corporate Overview
Corporate Overview • DLPL Strategy for future growth • Experienced Management team 13
Slide 14: DLPL Strategy for future growth
DLPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 14
Slide 15: DLPL Strategy for future growth
DLPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Lif
Slide 16: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Ved Prakash Goel Bharath Uppiliappan Shankha Banerjee Chief Financial Officer Chief Operating Officer Chief Gro
Slide 17: Shareholding as of 30th June, 2018
Shareholding as of 30th June, 2018 57.4% 7.9% 15.9% Promoter and Mutual FII Promoter Fund Group 18.8% Others 17
Slide 18: Contact us
Contact us About Dr Lal PathLabs Limited (DLPL) For further information please contact: Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. Ved Goel / Rajat Kalra It has an integrated nationwide network, where patients Dr. Lal PathLabs Limited and heal